Handok strengthens tie-ups with Nycomed

Published: 2010-04-02 06:56:00

Updated: 2010-04-02 06:56:00

Handok Pharm says its has signed an licensing agreement with Nycomed International Management GmbH, a global pharmaceutical company headquartered in Zurich, Switzerland for the exclusive distribution rights in Korea of Roflumilast, a new phosphodiesterase 4 inhibitor for chronic obstructive pulmo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK